Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies - Atreya, Raja; Feagan, B.; Shchukina, O.; Jairath, V.; Rieder, F.; Hisamatsu, T.; Siegmund, B.; Rizzo, J.; Kligys, K.; Neimark, E.; Song, A.; Zambrano, J.; et al. (JOURNAL OF CROHNS & COLITIS, 2022)
CRIS-Team WoS Importer:2022-05-13